Since angiotension II-dependent WNK4-SPAK-(p)NCC activation was present in CMA, the AT1R blocker and/or NCC inhibitors should be used with caution in such setting to avoid the exacerbated natriuresis, worsening metabolic acidosis and even hypokalemia. The gene discussed is AGTR1; the disease is Hypokalemia.